Study summary
A BTK inhibitor pill raised platelets for months in people who had failed many treatments
23%durable platelet response, vs 0% with placebo
What was tested
Rilzabrutinib, a twice-daily BTK inhibitor pill that calms the immune attack on platelets, against placebo, in adults with persistent or chronic ITP.
What they found
- Durable platelet response: 23% with rilzabrutinib vs 0% with placebo.
- 64% had an early platelet response, within a median of 15 days in responders.
- Rescue treatment use fell 52%, and bleeding and fatigue improved.
What it means
The first BTK inhibitor approved for ITP, adding an oral option with a new mechanism.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.